44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
We present updated results from a phase 1 dose-escalation study (NCT05067283) of selective KRAS G12C inhibitor MK-1084 as monotherapy in advanced solid tumors and in combination with pembrolizumab (pembro) for first-line metastatic NSCLC. Eligible pts had locally advanced unresectable/metastatic solid tumors and ≥1 line of prior therapy (Arm 1), or previously untreated metastatic NSCLC with PD-L1 TPS ≥1% (Arm 2), with histologic/blood-based confirmation of KRAS G12C mutation, measurable disease per RECIST v1.1 and ECOG PS ≤1. Pts received MK-1084 PO QD or BID (25–800 mg) as monotherapy (Arm 1) or with pembro 200 mg Q3W (Arm 2) using a modified toxicity probability dose-escalation design. Treatment continued until PD, unacceptable toxicity, withdrawal, or maximum permitted cycles (≤35 cycles for pembro; no limit for MK-1084). Primary endpoints were dose-limiting toxicities (DLTs), AEs and discontinuations due to AEs. AEs were graded per NCI CTCAE v5.0. ORR per RECIST v1.1 by investigator review was a secondary endpoint. As of Aug 4, 2023, 54 pts received MK-1084 in Arm 1 and 24 received MK-1084 plus pembro in Arm 2. Median (range) follow-up was 8.1 (1.5–18.4) mo in Arm 1 and 5.2 (0.2–14.1) mo in Arm 2. Arm 1 included 37 pts (69%) with CRC and 11 (20%) with NSCLC; 39 pts (72%) had ≥2 lines of prior therapy. No DLTs occurred in Arm 1. One pt in Arm 2 receiving MK-1084 400 mg QD + pembro experienced DLTs (grade 3 increased alanine aminotransferase [ALT] and grade 3 increased aspartate aminotransferase [AST]). AEs of any cause occurred in 96% of pts in Arm 1 and 96% in Arm 2. Treatment-related AEs (TRAEs) occurred in 57% of pts in Arm 1 and 79% in Arm 2. 9% and 42% experienced grade 3-4 TRAEs (no grade 5). The most common TRAEs across all dose levels were increased ALT (Arm 1, 15%; Arm 2, 42%), increased AST (17%; 33%), and diarrhea (13%; 17%). ORR was 22% (12/54 pts, all confirmed PR; 6 in CRC, 5 in NSCLC, and 1 pt with cervical adenocarcinoma) in Arm 1 and 71% (15/21 pts, all confirmed PR) in Arm 2. MK-1084 as monotherapy and in combination with pembro showed manageable safety and preliminary antitumor activity in pts with previously treated solid malignancies and previously untreated NSCLC with KRAS G12C mutations.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it